Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Japanese Children With Pulmonary Arterial Hypertension
NCT07646860Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Sep 2026; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07646860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646860.